Navigation Links
Criteria based on CT imaging after chemotherapy may help predict survival
Date:12/1/2009

Preliminary research suggests that criteria based on computed tomography (CT) imaging of changes in tumors from colorectal liver metastases after chemotherapy with the drug bevacizumab may have the potential to predict overall survival, according to a study in the December 2 issue of JAMA.

The addition of bevacizumab to cytotoxic (toxic to cells) chemotherapy is associated with improved survival in patients with stage IV colorectal cancer and higher pathologic response rates in patients undergoing resection (surgical removal) of colorectal liver metastases. "Recently, pathologic response to preoperative chemotherapy has been shown to correlate with improved survival and has been proposed as a new outcome end point after resection of colorectal liver metastases. To date, a noninvasive method of predicting pathologic response to chemotherapy in colorectal liver metastases, particularly biologic agents, is lacking," the authors write. They add that it has been observed that after bevacizumab-containing therapy, colorectal liver metastases tend not only to decrease in size but also to undergo unique morphologic (form and structure) changes on CT.

Yun Shin Chun, M.D., of the University of Texas M. D. Anderson Cancer Center, Houston, and colleagues conducted a study to validate tumor response criteria that are based on morphologic changes observed on CT in patients with colorectal liver metastases treated with bevacizumab-containing chemotherapy regimens. The researchers analyzed a total of 234 colorectal liver metastases from 50 patients who underwent hepatic resection (removal of tumors involving the liver) after preoperative chemotherapy that included bevacizumab, from 2004 to 2007; date of last follow-up was March 2008. All patients underwent routine contrast-enhanced CT at the start and end of preoperative therapy. Radiologists evaluated images for morphologic response, based on metastases changing from heterogeneous masses with ill-defined margins into homogeneous lesions with sharp borders. These criteria were validated with a separate group of 82 patients with unresectable (unable to be removed by surgery) colorectal liver metastases treated with bevacizumab-containing chemotherapy.

The researchers found that "morphologic criteria correlated strongly with the percentage of residual tumor cells and also with pathologic response stratified as complete, major, or minor using 50 percent residual tumor cells as the cutoff value between major and minor pathologic response. Optimal morphologic response to preoperative therapy translated into a survival benefit after hepatic resection. In a separate validation cohort of patients with unresectable colorectal liver metastases, response by morphologic criteria was also associated with improved overall survival."

The authors add that although the sample size in the surgical group was small, "these results highlight the importance of response rather than baseline clinical factors in determining patient outcome after liver resection."

" our results indicate that morphologic response may be a useful, noninvasive surrogate marker of pathologic response and improved survival in patients with colorectal liver metastases receiving a bevacizumab-containing regimen. It provides complementary information to traditional size-based criteria in assessing CT response to bevacizumab in colorectal liver metastases."


'/>"/>

Contact: Laura Sussman
lsussman@mdanderson.org
713-745-2457
JAMA and Archives Journals
Source:Eurekalert

Related medicine news :

1. Kraft Foods First Company to Adopt Smart Choices Program Nutrition Criteria for Advertising to Children in the U.S.
2. AllMeds' EMR Receives CCHIT 2008 Certification Software Complies with 100 Percent of Certification Criteria
3. HIMSS Electronic Health Record Association Supports Achievable Meaningful Use Criteria in Comments to ONC
4. Blue Cross/Blue Shield Of Massachusetts Introduces Controversial Criteria For Vein Treatment Reimbursement
5. HIMSS Electronic Health Record Association Executives Testify at NCVHS Hearings on Meaningful Use Criteria
6. Together Rx Access(R) Program Expands Eligibility Criteria, Responds to Challenging Economic Times
7. New criteria for measuring tumor size and progression will help ease workloads in clinical trials
8. New appropriate use criteria guide treatment of patients with heart blockage
9. Eligibility criteria contribute to racial disparities in hospice use
10. New Criteria Could Expand Number of Liver Transplant Candidates
11. How Patients Can Meet the Criteria for Insulin Pump Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... San Francisco, CA (PRWEB) , ... January 19, 2017 , ... ... and financial planning assistance to commercial and residential clients in the California Bay Area, ... promote positive heart health in the region. , Heart disease is the primary killer ...
(Date:1/19/2017)... ... 19, 2017 , ... Attorney Robert “RC” Pate , founder of The ... the Triumph Over Kid Cancer foundation. Each year, 175,000 children are diagnosed with pediatric ... firsthand the effect of the critical funding gap for research into pediatric cancer research. ...
(Date:1/19/2017)... , ... January 19, 2017 , ... Connecticut Dermatology Group ... Kim, a highly experienced and compassionate dermatologist. Dr. Kim brings an extensive background ... , “It is with considerable pleasure to welcome back Dr. Kim to the CDG ...
(Date:1/19/2017)... ... 19, 2017 , ... Each year, the Southeastern Society of ... hundreds of surgeons from over fifteen different countries come together to share and ... augmentation to breast reconstruction for breast cancer patients, teaching these surgical techniques ...
(Date:1/18/2017)... ... 2017 , ... From a health perspective, 2017 will clearly be the Year ... chronic disease, mental health and general physical well-being. The New York Times suggested a ... , For one Charlottesville restaurant, good gut health is clearly on the menu. ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , January 19, 2017 ... administration appears serious about reducing the FDA,s regulatory ... innovation in the medical drug industry, many of ... with new clinical trials and development of advanced ... forging ahead with recent developments include:  Moleculin Biotech, ...
(Date:1/19/2017)... 2017  ViewRay, Inc. (Nasdaq: VRAY ... clinical MRI-guided radiation therapy system, announced today that it ... million through a private placement of its common ... financing and was joined by certain of ViewRay,s ... Venture Partners, and an additional new institutional investor, ...
(Date:1/19/2017)... ROCKVILLE, Md. , Jan. 18, 2017 /PRNewswire/ ... a late-stage clinical company developing therapeutics designed to ... health of patients, today confirmed plans to initiate ... the Company,s modified-release reformulation of lovastatin lactone designed ... M. smithii) in the gut to treat ...
Breaking Medicine Technology: